Adaptive Biotechnologies Corp (ADPT)vsInsmed Inc (INSM)
ADPT
Adaptive Biotechnologies Corp
$14.15
+1.80%
HEALTHCARE · Cap: $2.14B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 119% more annual revenue ($606.42M vs $276.98M). INSM leads profitability with a -2.1% profit margin vs -21.5%. INSM earns a higher WallStSmart Score of 39/100 (F).
ADPT
Avoid32
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.0% year-over-year
No standout strengths identified
Areas to Watch
Trading at 10.0x book value
0.0% earnings growth
Elevated debt levels
ROE of -27.8% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 51.0% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ADPT
The primary concerns for ADPT are Price/Book, EPS Growth, Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ADPT profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.30 — expect wider price swings.
ADPT is growing revenue faster at 51.0% — sustainability is the question.
ADPT generates stronger free cash flow (1M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?